Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.
Publication
, Journal Article
Ison, MG; Wolfe, C; Boucher, HW
Published in: JAMA
June 16, 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
June 16, 2020
Volume
323
Issue
23
Start / End Page
2365 / 2366
Location
United States
Related Subject Headings
- United States
- SARS-CoV-2
- Pneumonia, Viral
- Pandemics
- Humans
- General & Internal Medicine
- Emergencies
- Drug Approval
- Coronavirus Infections
- COVID-19 Drug Treatment
Citation
APA
Chicago
ICMJE
MLA
NLM
Ison, M. G., Wolfe, C., & Boucher, H. W. (2020). Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. JAMA, 323(23), 2365–2366. https://doi.org/10.1001/jama.2020.8863
Ison, Michael G., Cameron Wolfe, and Helen W. Boucher. “Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.” JAMA 323, no. 23 (June 16, 2020): 2365–66. https://doi.org/10.1001/jama.2020.8863.
Ison MG, Wolfe C, Boucher HW. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. JAMA. 2020 Jun 16;323(23):2365–6.
Ison, Michael G., et al. “Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.” JAMA, vol. 323, no. 23, June 2020, pp. 2365–66. Pubmed, doi:10.1001/jama.2020.8863.
Ison MG, Wolfe C, Boucher HW. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. JAMA. 2020 Jun 16;323(23):2365–2366.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
June 16, 2020
Volume
323
Issue
23
Start / End Page
2365 / 2366
Location
United States
Related Subject Headings
- United States
- SARS-CoV-2
- Pneumonia, Viral
- Pandemics
- Humans
- General & Internal Medicine
- Emergencies
- Drug Approval
- Coronavirus Infections
- COVID-19 Drug Treatment